Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 14/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040234 | 1.00 | NPY5R (0.51) | NPY5RADRA1AKCNH2HSD11B1SMN1; SMN2 | |
| SCHEMBL3032797 | 0.90 | NPY5R (0.51) | NPY5RADRA1AKCNH2HSD11B1KDM4E | |
| SCHEMBL3668430 | 0.84 | NPY5R (0.54) | NPY5RADRA1AKCNH2HSD11B1 | |
| SCHEMBL3668431 | 0.84 | NPY5R (0.54) | NPY5RADRA1AKCNH2HSD11B1 | |
| SCHEMBL13045628 | 0.84 | NPY5R (0.52) | NPY5RADRA1AKCNH2HSD11B1ALDH1A1 | |
| SCHEMBL13045562 | 0.84 | NPY5R (0.52) | NPY5RADRA1AKCNH2HSD11B1ALDH1A1 | |
| SCHEMBL3027552 | 0.84 | NPY5R (0.52) | NPY5RADRA1AKCNH2HSD11B1ALDH1A1 | |
| SCHEMBL3028742 | 0.83 | NPY5R (0.53) | NPY5RADRA1AKCNH2HSD11B1 | |
| SCHEMBL13045661 | 0.83 | NPY5R (0.52) | NPY5RADRA1AKCNH2HSD11B1ALDH1A1 | |
| Lithium Ion SCHEMBL3021432 | 0.83 | NPY5R (0.52) | NPY5RADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| WO-2008129007-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | NPY5R, NPY4R, NPY1R | NPY5R 1/4885ADRA1A 340/4885KCNH2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.